R & D Day

Five Prime 2015 R & D Day

Cabiralizumab (FPA008)

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients with Rheumatoid Arthritis (RA): Preliminary Results

cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models Poster

cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Subjects with Rheumatoid Arthritis (RA): Preliminary Results

A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers Poster

A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results

Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells
Wei S, Nandi S, Chitu V, et al.
J Leukoc Biol
2010;88:495–505.

Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome Lin et al.
Science 9 May 2008: 807-811
DOI: 10.1126/science.1154370

FPA144

Antitumor Activity and Safety of FPA144, an ADCC enhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer and Advanced Solid Tumors

FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 Blockade in the 4T1 Syngeneic Tumor Model in Mice

FPA144: A Therapeutic Monoclonal Antibody with Enhanced Antibody-Dependent Cell Killing for the Treatment of Fibroblast Growth Factor Receptor 2b Overexpressing Cancers

FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 the 4T1 Breast Tumor Model in Mice

FPA144-001: A First in Human Study of FPA144, an ADCC-enhanced, FGFR2b Isoform-selective Monoclonal Antibody in Patients with Advanced Solid Tumors

FPA144: A Therapeutic Antibody for Treating Patients with Gastric Cancers Bearing FGFR2 Gene Amplification

FP-1039

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) with deregulated fibroblast growth factor (FGF) pathway signaling: interim results in MPM

FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF)pathway deregulated squamous NSCLC or MPM

Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
Harding, et al.
Sci Transl Med 27 March 2013:
Vol. 5, Issue 178, p. 178ra39

Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

Supplemental Materials

Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1

Preliminary Results of a Dose Escalation Study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) In Patients With Advanced Malignancies

Enrolling a Rare Patient Population: Establishing Proof of Concept for FP-1039,an FGF “Trap,” in Endometrial Cancer Patients with the S252W FGFR2 Mutation

Preclinical Effi cacy of FP-1039 (FGFR1:Fc) in Endometrial Carcinoma Models with Activating Mutations in FGFR2

Preliminary Results of a Phase 1 Study of FP-1039 (FGFR1:Fc), A Novel Antagonist Of Multiple Fibroblast Growth Factor (FGF) Ligands, In Patients With Advanced Malignancies

Preclinical Antitumor Efficacy of FP-1039, A Soluble FGF Receptor 1:Fc Conjugate, as a Single Agent or in Combination with Anticancer Drugs

FP-1039 (FGFR1:Fc), A Soluble FGFR1 Receptor Antagonist, Inhibits Tumor Growth and Angiogenesis

Discovery Platform, Immuno-Oncology Research, and Respiratory Research

A High Content Screen to Identify Novel Factors That Restore Phagocytosis in COPD Alveolar Macrophages

An in vitro Co-culture Model to Characterize Cross-talk between COPD Airway Epithelia and Dendritic Cells

Discovery of Novel Immune Checkpoint Regulators in a Comprehensive Library of Human Extracellular Proteins

Deorphanization of the human leukocyte tyrosinekinase (LTK) receptor by a signaling screen of the extracellular proteome

Controlling Feature Selection in Random Forests of Decision Trees Using a Genetic Algorithm: Classification of Class I MHC Peptides.

HTS Technologies in Biopharmaceutical Discovery
Ge Wu, Stephen K. Doberstein
Volume 11, Issues 15–16, August 2006, Pages 718–724
Drug Discovery Today, 11:15-16.

IO Research and Preclinical

Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology Poster

Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology

Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo Poster

Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo